Psoriasis Treatment Market Forecast 2035: Top Trends Shaping the Future Scope
Psoriasis Treatment Market Outlook and Forecast
The Psoriasis Treatment Market continues to witness significant advancements driven by increasing awareness of chronic skin disorders, expanding biologic therapies, and continuous pharmaceutical innovation. Rising healthcare expenditure, favorable reimbursement policies, and the growing adoption of personalized medicine are supporting market expansion across developed and emerging economies. Pharmaceutical companies are investing heavily in advanced immunology research to introduce therapies with improved efficacy, enhanced safety profiles, and long-term disease management capabilities.
In 2025, the psoriasis treatment market was valued at USD 32.95 Billion. The market is projected to reach USD 79.45 Billion by 2035, expanding at a 9.2% CAGR during 2026–2035. The increasing prevalence of autoimmune diseases, rising diagnosis rates, and growing availability of biologics and biosimilars are expected to support sustained market growth throughout the forecast period.
Regional Performance Highlights
North America remains the leading regional market due to high healthcare spending, widespread access to advanced biologic therapies, favorable reimbursement frameworks, and ongoing clinical research. The United States continues to dominate regional revenue owing to strong pharmaceutical innovation and increasing patient awareness.
Europe represents a mature market supported by expanding biosimilar adoption, government healthcare initiatives, and strong regulatory support for innovative dermatology treatments. Countries including Germany, France, and the UK continue to invest in advanced therapeutic options.
Asia Pacific is emerging as one of the fastest-growing regional markets owing to increasing healthcare infrastructure, rising diagnosis rates, expanding pharmaceutical manufacturing, and greater patient access to specialty medications across China, India, Japan, and South Korea.
Market Segment Analysis
Retail Pharmacies: The retail pharmacies segment contributed a 51.5% share of the psoriasis treatment market in 2025. The widespread availability of prescription medicines, convenient patient access, and expanding pharmacy networks continue to strengthen this segment.
Parenteral Route: The parenteral segment accounted for a 43.26% share of the market in 2025. The increasing adoption of injectable biologics and monoclonal antibodies for moderate-to-severe psoriasis has significantly contributed to segment leadership.
Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/21373
Top Market Trends Transforming the Psoriasis Treatment Market
Growing Adoption of Biologic Therapies
Biologic drugs targeting cytokines such as IL-17, IL-23, and TNF-alpha continue transforming psoriasis management by providing superior clinical outcomes compared to conventional systemic therapies. Pharmaceutical manufacturers are expanding biologic portfolios while improving dosing convenience and long-term efficacy.
Expansion of Biosimilars
Biosimilars are becoming increasingly important in improving patient affordability and expanding treatment accessibility. Healthcare providers and governments are encouraging biosimilar adoption to reduce treatment costs while maintaining comparable therapeutic effectiveness.
Personalized Medicine and Precision Therapeutics
Advancements in genomic research and biomarker identification are enabling more personalized treatment strategies. Physicians are increasingly selecting therapies based on disease severity, patient response, genetic factors, and comorbidities, leading to improved treatment outcomes and patient satisfaction.
Digital Healthcare Integration
Teledermatology platforms, remote patient monitoring, digital adherence tools, and AI-assisted diagnostics are enhancing patient engagement and improving long-term disease management. These technologies allow dermatologists to monitor treatment effectiveness while reducing unnecessary hospital visits.
Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/21373
Recent Company Developments
- Johnson & Johnson continued expanding the global commercialization of its IL-23 inhibitor while strengthening clinical research programs focused on improving long-term psoriasis management.
- AbbVie Inc. advanced new clinical studies evaluating next-generation immunology therapies and continued investments supporting broader access to its established biologic portfolio.
- Amgen Inc. expanded biosimilar development initiatives and strengthened manufacturing capabilities to support increasing global demand for biologic therapies.
- Novartis AG continued enhancing its dermatology portfolio through ongoing research, additional regulatory approvals, and lifecycle management strategies for psoriasis treatments.
- Eli Lilly and Company invested in expanding production capacity while advancing innovative biologic therapies targeting moderate-to-severe plaque psoriasis.
- UCB S.A. strengthened its immunology business through additional clinical evidence supporting the long-term effectiveness and safety of its psoriasis therapies.
- Bristol Myers Squibb continued strategic investments in autoimmune disease research while advancing pipeline candidates addressing inflammatory skin disorders.
- Sun Pharmaceutical Industries Ltd. expanded its dermatology product portfolio and continued strengthening its presence across emerging healthcare markets through new product launches and commercialization strategies.
- Pfizer Inc. continued advancing research collaborations focused on innovative immune-mediated disease therapies while supporting expanded access to existing treatment options.
- LEO Pharma continued investing in dermatology-focused innovation, including topical therapies and next-generation treatment solutions designed to improve patient outcomes.
Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/21373
Related Reports
About Fundamental Business Insights:
Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.
Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email: sales@fundamentalbusinessinsights.com
